18/12
AusCann completed manufacturing and testing of the hard-shell capsules and released the hard-shell capsules for clinical evaluation.
The hard-shell capsules were tested and found to meet all applicable pre-defined criteria set by the Australian Therapeutic Goods Administration, relevant International Pharmacopoeial standards, and the company’s own quality assurance and control procedures.
AusCann is now targeting hard-shell capsules availability for patients in Australia during the first half of calendar year 2020.